Granite Point Capital Management’s Adicet Bio ACET Stock Holding History

Granite Point Capital Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,108	Closed	-$379K	–	3
2023 Q1	$379K	Buy	4,108 +1,295	+46%	+$163K	0.53%	31
2022 Q4	$402K	Hold	2,813	–	–	0.26%	63
2022 Q3	$640K	Sell	2,813 -9,556	-77%	-$2.43M	0.26%	59
2022 Q2	$2.89M	Hold	12,369	–	–	0.74%	14
2022 Q1	$3.95M	Hold	12,369	–	–	0.82%	25
2021 Q4	$3.46M	Hold	12,369	–	–	0.59%	36
2021 Q3	$1.55M	Sell	12,369 -2,365	-16%	-$293K	0.12%	81
2021 Q2	$2.43M	Sell	14,734 -266	-2%	-$54.2K	0.09%	70
2021 Q1	$3.14M	Buy	+15,000	New	+$3.44M	0.12%	66

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Granite Point Capital Management's ACET Position: Q2 2023 in Review

Granite Point Capital Management sold out of Adicet Bio (ACET) in Q2 2023, closing a stake of 4,108 shares — an estimated $379K sold.

Granite Point Capital Management first reported a position in ACET in Q1 2021 and held it in 9 quarters. The position peaked at $3.95M in Q1 2022. 94 funds tracked by Wall St. Rank hold ACET as of Q2 2023.

Granite Point Capital Management reported no remaining Adicet Bio position as of Q2 2023 after selling out during the quarter.
Granite Point Capital Management sold 4,108 Adicet Bio shares in Q2 2023, an estimated $379K.
Granite Point Capital Management first reported a position in Adicet Bio in Q1 2021 and held it in 9 quarters.
Granite Point Capital Management's Adicet Bio position peaked at $3.95M in Q1 2022.
94 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2023.

Based on Granite Point Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.